Earnings Call · Q1 FY2024·2024-05-09

Q1 24EPS 0.00%·Rev n/aQ4 23EPS +7.14%·Rev n/aQ3 23EPS -75.00%·Rev n/aQ2 23EPS 0.00%·Rev n/a⚠ consensus missing

Cytosorbents Corp CTSO

Eric Ribner — Investor Relations (or similar, e.g., Head of IR/Communications)

Phillip Chan — Chief Executive Officer

Kathleen Bloch — Chief Financial Officer

Efthymios Deliargyris — Chief Medical Officer (or similar clinical/regulatory leadership role)

For the second criteria, the device must meet at least one of the following considerations

+12.3%1d on move date+12.2% vs SPY3d+2.7%5d+7.0%

Research tier

Behavioral profile computed for 5 speakers on this call.

Sign in to view the Behavioral Lean, the Behavioral Deviation Score, the speaker decomposition, and the novel forward-guidance phrases flagged on this call — each scored against the speaker's own prior-call baseline.

Behavioral data on every earnings call

Per-speaker language deviation, scored against each executive's own history. Explore more CTSO calls or request research access.

More CTSO calls Browse calls Request research access